Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Discontinued OperationsCash from Discontinued OperationsCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Mimedx (MDXG) Long-Term Debt Repayments (2011 - 2024)

Mimedx recorded quarterly Long-Term Debt Repayments of $30.0 million in Q1 2024, up 2999900.0% quarter-over-quarter from $1000.0 in Q4 2018.

Mimedx's Long-Term Debt Repayments history runs 4 years deep, the most recent figure standing at $30.0 million for Q1 2024.

  • In Q1 2024, Long-Term Debt Repayments changed N/A year-over-year to $30.0 million; the TTM figure through Dec 2024 stood at $30.0 million (changed N/A YoY), while the FY2024 annual figure was $30.0 million, changed N/A from the prior year.
  • Long-Term Debt Repayments came in at $30.0 million for Q1 2024 at Mimedx, up from $1000.0 in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $30.0 million in Q1 2024 to a low of $30.0 million in Q1 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Repayments (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Mimedx 530.69 Mn 370.92 Mn 41.62 Mn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2024 30.00 Mn
Mar 31, 2024 30.00 Mn
Dec 31, 2018 1,000.00
Dec 31, 2018 1,000.00
Sep 30, 2018 -1,000.00
Sep 30, 2018 -1,000.00
Dec 31, 2012 -126.00
Dec 31, 2012 -126.00
Sep 30, 2012 177,126.00
Sep 30, 2012 177,126.00
Mar 31, 2012 250,000.00
Mar 31, 2012 250,000.00
Dec 31, 2011 88,657.00
Dec 31, 2011 88,657.00
Jun 30, 2011 -15,376.00
Jun 30, 2011 -15,376.00
Mar 31, 2011 15,376.00
Mar 31, 2011 15,376.00